Cytokinetics (CYTK) Times Interest Earned (2012 - 2025)
Cytokinetics (CYTK) posted quarterly Times Interest Earned of -$115.85 for Q1 2026, down 618.1% year-over-year from $22.36 in Q1 2025, and down 256.2% quarter-over-quarter from $74.16 in Q4 2025.
Powered by 
Analysis
Cytokinetics (CYTK) Times Interest Earned (2012 - 2025) Analysis & Trends
Cytokinetics (CYTK) has reported Times Interest Earned for 16 consecutive years, with -$115.85 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 618.1% year-over-year to -$115.85; the TTM figure through Mar 2026 stood at -$32.16 (down 132.08% YoY), while the FY2025 annual figure was -$2.0, down 166.52% from the prior year.
- Times Interest Earned eased to -$115.85 in Q1 2026 per CYTK's latest filing, from $74.16 in the prior quarter.
- Across five years, Times Interest Earned topped out at $74.16 in Q4 2025 and bottomed at -$115.85 in Q1 2026.
- Historically, Times Interest Earned has averaged -$12.34 across 5 years, with a median of -$12.37 in 2024.
- Annual changes were most pronounced in 2022 — Times Interest Earned sank 1275.97% — and 2025, when it jumped 607.75%.
- Cytokinetics' Times Interest Earned stood at -$9.17 in 2022, then soared by 228.16% to $11.75 in 2023, then sank by 224.34% to -$14.61 in 2024, then surged by 607.75% to $74.16 in 2025, then plunged by 256.2% to -$115.85 in 2026.
- Business Quant data shows CYTK's Times Interest Earned at -$115.85 in Q1 2026, $74.16 in Q4 2025, and -$7.53 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -12.50 |
| Sep 30, 2025 | -14.69 |
| Jun 30, 2025 | -10.06 |
| Dec 31, 2024 | -15.56 |
| Sep 30, 2024 | -15.77 |
| Jun 30, 2024 | -10.22 |
| Mar 31, 2024 | -17.77 |
| Dec 31, 2023 | -17.79 |
| Sep 30, 2023 | -17.13 |
| Jun 30, 2023 | -17.32 |
| Mar 31, 2023 | -17.88 |
| Dec 31, 2022 | -18.00 |
| Sep 30, 2022 | -15.94 |
| Jun 30, 2022 | -3.87 |
| Mar 31, 2022 | -11.86 |
| Dec 31, 2021 | -5.15 |
| Sep 30, 2021 | -16.63 |
| Jun 30, 2021 | -13.45 |
| Mar 31, 2021 | -10.18 |
| Dec 31, 2020 | -6.44 |